Prader-Willi Syndrome (PWS) is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Prader-Willi Syndrome (PWS) have a 50% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Prader-Willi Syndrome (PWS) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Prader-Willi Syndrome (PWS) overview
Prader-Willi syndrome (PWS) is a rare congenital genetic disorder that results in a number of physical, mental, and behavioral problems. PWS is due to the lack of several genes on one of an individual’s two chromosome 15s. In the majority of cases, there is a deletion. In the remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15’s from the mother (uniparental disomy). Symptoms include poor muscle tone, low levels of sex hormones, and a constant feeling of hunger.
For a complete picture of PTSR and LoA scores for drugs in Prader-Willi Syndrome (PWS), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
